Randomized trial examines CCR5 and CD74 targeting to reduce necroinflammation in kidney damage, suggesting innovative therapeutic approaches.
Key Points
This study aims to identify potential therapeutic targets for necroinflammation associated with cholesterol crystal embolism (CCE).
Utilized a C57BL/6J mouse model with unilateral renal artery cholesterol crystal injection.
Performed single-cell transcriptomics to analyze changes in kidney cell types, identifying differentially expressed genes.
Administered pharmacological inhibitors of CCR5 (maraviroc) and CD74 (milatuzumab) to assess impact on vascular damage and acute kidney injury.
A total of 1659 differentially expressed genes were found in the ascending loop of Henle, and 1505 in proximal tubules, indicating significant cellular changes.
Combined inhibition of CCR5 and CD74 reduced vascular thrombosis and tissue damage, demonstrating effectiveness even with delayed treatment.
Post-treatment reduced complications of thrombotic angiopathy and acute kidney injury, suggesting therapeutic potential for CCR5 and CD74.